Knowthestock.com
AMGN - AMGEN Inc.
SNP 500DOW 30NASDAQ

Sell

Moderate Growth but Declining
WeakStrong
WeakStrong

48%

based on last 5 year data.
Income Statement is MODERATE
Revenue Growth is 3.53%
Operating Income Growth is 26.15%
Net Income Growth is 14.44%
Earnings Per Share (EPS) Growth is 19.94%
Net Margin is 24.92%
Balance Sheet is WEAK
Current Asset to Current Liability Ratio is 1.53
Debt Ratio is 0.26
Current Debt to Net Income Ratio is 0.62
Total Debt to Total Assets Ratio is 0.63
Cash Flow is MODERATE
Cash from Operations Growth is -2.47%
Capital Expenditure is Low
Net Increase in Cash is Negative
Long Term Score Trend is NEGATIVE
Investment Risk is Low
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
AMGEN Inc. (AMGN) - www.amgen.com
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Exchange - NASDAQ
Industry - Biological Product (except Diagnostic) Manufacturing
Sector - Manufacturing
CEO - Robert Bradway
Employees - 24,300
    Close

    Login/Register

    Home


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2022 and future.